Review





Similar Products

class b cpg odn  (InvivoGen)
94
InvivoGen class b cpg odn
Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
Class B Cpg Odn, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/ODN+1018+VacciGrade/pmc13260544-43-11-15
Average 94 stars, based on 1 article reviews
class b cpg odn - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
tlr9 agonist 166  (MedChemExpress)
94
MedChemExpress tlr9 agonist 166
Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
Tlr9 Agonist 166, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/ODN+1018/pm41791624-84-0-9
Average 94 stars, based on 1 article reviews
tlr9 agonist 166 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
odn 1018 vaccigrade  (InvivoGen)
94
InvivoGen odn 1018 vaccigrade
Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG <t>ODN,</t> and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.
Odn 1018 Vaccigrade, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/ODN+1018+VacciGrade/pm42066777-352-25-28
Average 94 stars, based on 1 article reviews
odn 1018 vaccigrade - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
odn 1018 vaccigradetm  (InvivoGen)
94
InvivoGen odn 1018 vaccigradetm
Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
Odn 1018 Vaccigradetm, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/ODN+1018+VacciGrade/pmc13124971-89-24-36
Average 94 stars, based on 1 article reviews
odn 1018 vaccigradetm - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
cpg odn 1018s  (Sangon Biotech)
86
Sangon Biotech cpg odn 1018s
Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
Cpg Odn 1018s, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/1018s+cpg/pmc12474238-57-1-11
Average 86 stars, based on 1 article reviews
cpg odn 1018s - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
cpg 1018® (cpg odn 1018) adjuvant  (Dynavax Technologies)
90
Dynavax Technologies cpg 1018® (cpg odn 1018) adjuvant
Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
Cpg 1018® (Cpg Odn 1018) Adjuvant, supplied by Dynavax Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/cpg+1018/us12364745-169-10-2
Average 90 stars, based on 1 article reviews
cpg 1018® (cpg odn 1018) adjuvant - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cpg odn 1018s adjuvant  (Sangon Biotech)
90
Sangon Biotech cpg odn 1018s adjuvant
Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
Cpg Odn 1018s Adjuvant, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/cpg+1018s/pm40354699-69-1-8
Average 90 stars, based on 1 article reviews
cpg odn 1018s adjuvant - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
odn1018  (MedChemExpress)
94
MedChemExpress odn1018
Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.
Odn1018, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/odn+1018/ODN+1018/pm40140567-591-25-27
Average 94 stars, based on 1 article reviews
odn1018 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG ODN, and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.

Journal: Frontiers in Immunology

Article Title: Preliminary evaluation of a DDA cationic liposome-based pulmonary mucosal immunization platform carrying a SARS-CoV-2 spike-derived branched peptide

doi: 10.3389/fimmu.2026.1824741

Figure Lengend Snippet: Expression of co-stimulatory molecules and MHC II on BMDCs after treatment with different formulations. (A) CD86+MHC II+ BMDCs; (B) CD80+MHC II+ BMDCs; (C) CD86+ expression in BMDMs; (D) IFN-γ levels in BMDC culture supernatants; (E) BMDC viability assessed by CCK-8 assay. The treatment groups included PBS, soluble peptide antigen (S450-471), soluble CpG ODN, and S 450-471 @DDA-Lipo+CpG. N = 3 per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparisons test versus the control group. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ns, not significant.

Article Snippet: The adjuvant used in this study was CpG ODN 1018, a class B CpG ODN (InvivoGen, San Diego, CA, USA; cat. vac-1018-1), with the sequence 5′-TGACTGTGAACGTTCGAGATGA-3′.

Techniques: Expressing, CCK-8 Assay, Control

Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Journal: Frontiers in Immunology

Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

doi: 10.3389/fimmu.2026.1787216

Figure Lengend Snippet: Administration of OVA antigen formulated using ALTA ® platform elicits robust and durable antibody production measured using anti-OVA IgG1. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice received boost doses at week 6. Shown are the anti-OVA IgG1 titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I, J) . (A) Anti-OVA IgG1 titers (log10) over 12 weeks and (B) the geometric mean titers ratio (GMR) at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG1 titers (log10) over 14 weeks and (D) the GMR at week 4 (n = 10) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG1 titers (log10) before and after week 6 boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG1 (log10) at week 26 after one and two doses of 62.5 ng OVA/dose (n = 4–5) (I) or 250 ng OVA/dose (n = 3–5) (J) . Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , and AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

Techniques: Injection, Enzyme-linked Immunosorbent Assay, Adjuvant

Administration of antigen formulated using ALTA ® platform elicits antibody subtypes that align with a balanced Th1/Th2 response. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice were boosted at week 6. Shown are the anti-OVA IgG2c titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I) . (A) Anti-OVA IgG2c titers (log10) over 12 weeks and (B) the GMR at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG2c titers (log10) over 12 weeks and (D) the GMR at week 4 (n = 5) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG2c titers (log10) before and after boost at week 6 and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG2c titers (log10) before and after boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG2c (log10) at week 26 after one or two doses of 62.5 ng OVA/dose (n = 4–5) or 250 ng OVA/dose (n = 3–5). (J) The ratio of IgG2c (log10) to IgG1 (log10) at week 10 (1,000 ng OVA/dose, n = 3–5/group). Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant; GMR, geometric mean ratio.

Journal: Frontiers in Immunology

Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

doi: 10.3389/fimmu.2026.1787216

Figure Lengend Snippet: Administration of antigen formulated using ALTA ® platform elicits antibody subtypes that align with a balanced Th1/Th2 response. C57BL/6 mice were injected i.m. with 62.5 or 250 ng of OVA antigen delivered in ALTA ® platform or with adjuvants, including Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. Where indicated, the mice were boosted at week 6. Shown are the anti-OVA IgG2c titers measured via ELISA over the course of 12–14 weeks (A–H) and at week 26 (I) . (A) Anti-OVA IgG2c titers (log10) over 12 weeks and (B) the GMR at week 4 (n = 9–10) and week 10 (n = 5) (62.5 ng OVA). (C) Anti-OVA IgG2c titers (log10) over 12 weeks and (D) the GMR at week 4 (n = 5) and week 10 (n = 5) (250 ng OVA). (E) Anti-OVA IgG2c titers (log10) before and after boost at week 6 and (F) the GMR at week 4 after boost (n = 4–5) (62.5 ng OVA/dose). (G) Anti-OVA IgG2c titers (log10) before and after boost and (H) the GMR at week 4 after boost (n = 5) (250 ng OVA/dose). (I, J) Anti-OVA IgG2c (log10) at week 26 after one or two doses of 62.5 ng OVA/dose (n = 4–5) or 250 ng OVA/dose (n = 3–5). (J) The ratio of IgG2c (log10) to IgG1 (log10) at week 10 (1,000 ng OVA/dose, n = 3–5/group). Shown are representative data from one of two [ (A–H) : ALTA ® , Alhydrogel ® , AddaVax™ groups] or one experiment [ (A–H) : Alhydrogel ® + CpG group; (I, J) : all groups]. Mean ± SD (A, C, E, G, I, J) and geometric mean ratio ± 95% CI (B, D, F, H) . OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant; GMR, geometric mean ratio.

Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

Techniques: Injection, Enzyme-linked Immunosorbent Assay, Adjuvant

Administration of antigen formulated using ALTA ® platform elicits a more robust antigen (OVA)-specific CD8+ T-cell response than Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. C57BL/6 mice were i.m. immunized with 62.5 or 250 ng of OVA antigen delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Blood was collected at the indicated time points after prime (A–E) or boost (week 6) (F–H) and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry. (A) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells of total CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 2 post-vaccination. (B, C) The frequency of OVA-specific CD8+ T cells in blood at weeks 1, 2, 4, 8, and 10 after vaccinations with 62.5 (B) or 250 ng (C) OVA. The percentage of CD127 (IL-7Rα) and/or KLRG1-expressing (D) and Granzyme B+ (E) within OVA-specific CD8+ T cells after ALTA ® vaccination (250 ng OVA). (F) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 8 after prime (top row) and 2 weeks after boost (bottom row). The frequency of OVA-specific CD8+ T cells at week 8 after prime and 2 weeks after week 6 boost with 250 ng (G) and 62.5 ng OVA (H) . Shown are the representative data from one of two [ (A–E) : ALTA ® and Alhydrogel ® groups] or one experiment [ (A–D) : AddaVax™ and Alhydrogel ® + CpG ODN 1018 groups; (F–H) : all groups]. N = 4–10/group. Mean ± SEM. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Journal: Frontiers in Immunology

Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

doi: 10.3389/fimmu.2026.1787216

Figure Lengend Snippet: Administration of antigen formulated using ALTA ® platform elicits a more robust antigen (OVA)-specific CD8+ T-cell response than Alhydrogel ® , AddaVax™, and Alhydrogel ® + CpG ODN 1018. C57BL/6 mice were i.m. immunized with 62.5 or 250 ng of OVA antigen delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Blood was collected at the indicated time points after prime (A–E) or boost (week 6) (F–H) and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry. (A) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells of total CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 2 post-vaccination. (B, C) The frequency of OVA-specific CD8+ T cells in blood at weeks 1, 2, 4, 8, and 10 after vaccinations with 62.5 (B) or 250 ng (C) OVA. The percentage of CD127 (IL-7Rα) and/or KLRG1-expressing (D) and Granzyme B+ (E) within OVA-specific CD8+ T cells after ALTA ® vaccination (250 ng OVA). (F) Representative dot plots depicting the percentage of OVA-specific CD8+ T cells (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD8α+CD19− live lymphocytes) at week 8 after prime (top row) and 2 weeks after boost (bottom row). The frequency of OVA-specific CD8+ T cells at week 8 after prime and 2 weeks after week 6 boost with 250 ng (G) and 62.5 ng OVA (H) . Shown are the representative data from one of two [ (A–E) : ALTA ® and Alhydrogel ® groups] or one experiment [ (A–D) : AddaVax™ and Alhydrogel ® + CpG ODN 1018 groups; (F–H) : all groups]. N = 4–10/group. Mean ± SEM. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

Techniques: Flow Cytometry, Expressing, Adjuvant

The frequency and numbers of the total and cytokine-producing OVA-specific CD8+ T cells in the spleens are increased after ALTA ® immunization. C57BL/6 mice were i.m. immunized with 1,000 ng of OVA delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Indicated groups were boosted at week 6 after prime. (A–D) The spleens were collected at week 14 after prime and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD44+CD8α+CD19− live lymphocytes). (A) The percentage of OVA-specific CD8+ T cells of total CD8+ T cells. (B) The total number of OVA-specific CD8+ T cells per spleen. (C) The percentage and number (D) of CD127 (IL-7Rα) and/or KLRG1-expressing OVA-specific CD8+ T cells after ALTA ® OVA vaccination. (E–H) The splenocytes were re-stimulated with the OVA peptide pool for 5 h ex vivo , and the expression of IFN-γ, IL-2, and/or TNF-α was measured via intracellular cytokine staining. (E, F) The frequency (E) and number per spleen (F) of the CD8+ T cells expressing IFN-γ, IL-2, or TNF-α (gated as CD44+CD8α+CD19− live lymphocytes). (G, H) The frequency (G) and number per spleen (H) of the CD8+ T cells expressing two cytokines (IFN-γ+IL-2+, IFN-γ+TNF-α+, and IL-2+TNF-α+). N = 3–5/group. Mean ± SEM. Brown–Forsythe and Welch’s ANOVA Dunnett’s T3 multiple comparisons test between ALTA ® and other groups (at matching number of doses). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Journal: Frontiers in Immunology

Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

doi: 10.3389/fimmu.2026.1787216

Figure Lengend Snippet: The frequency and numbers of the total and cytokine-producing OVA-specific CD8+ T cells in the spleens are increased after ALTA ® immunization. C57BL/6 mice were i.m. immunized with 1,000 ng of OVA delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Indicated groups were boosted at week 6 after prime. (A–D) The spleens were collected at week 14 after prime and analyzed for presence and phenotype of the OVA-specific CD8+ T cells by flow cytometry (gated as H-2K b -SIINFEKL tetramer APC+ H-2K b -SIINFEKL tetramer BV421+ in CD44+CD8α+CD19− live lymphocytes). (A) The percentage of OVA-specific CD8+ T cells of total CD8+ T cells. (B) The total number of OVA-specific CD8+ T cells per spleen. (C) The percentage and number (D) of CD127 (IL-7Rα) and/or KLRG1-expressing OVA-specific CD8+ T cells after ALTA ® OVA vaccination. (E–H) The splenocytes were re-stimulated with the OVA peptide pool for 5 h ex vivo , and the expression of IFN-γ, IL-2, and/or TNF-α was measured via intracellular cytokine staining. (E, F) The frequency (E) and number per spleen (F) of the CD8+ T cells expressing IFN-γ, IL-2, or TNF-α (gated as CD44+CD8α+CD19− live lymphocytes). (G, H) The frequency (G) and number per spleen (H) of the CD8+ T cells expressing two cytokines (IFN-γ+IL-2+, IFN-γ+TNF-α+, and IL-2+TNF-α+). N = 3–5/group. Mean ± SEM. Brown–Forsythe and Welch’s ANOVA Dunnett’s T3 multiple comparisons test between ALTA ® and other groups (at matching number of doses). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

Techniques: Flow Cytometry, Expressing, Ex Vivo, Staining, Adjuvant

ALTA ® platform is antigen- and aluminum-sparing. C57BL/6 mice were i.m. immunized with 62.5, 250, or 1,000 ng of OVA antigen per dose delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Where indicated, the boost doses were administered at week 6 after prime. (A, B) Shown are the total OVA doses (ng) (X axis) by the mean anti-OVA IgG1 (log10) titers (Y axis) at week 4 after prime (A) and week 4 after boost (B) . The amount of aluminum (ng Al3+) delivered with each treatment is indicated as a color-coded number on the graph. The AddaVax™ group did not receive any aluminum and is labeled as “n/a” (not applicable). (C, D) Shown are the total OVA doses (ng) (X axis) by the mean percentage of the OVA-specific CD8+ T cells in blood (Y axis) at week 2 after prime (C) and week 2 after boost. (D) N = 4–5/group. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Journal: Frontiers in Immunology

Article Title: Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTA ® ) platform elicits enhanced humoral and cellular immune responses

doi: 10.3389/fimmu.2026.1787216

Figure Lengend Snippet: ALTA ® platform is antigen- and aluminum-sparing. C57BL/6 mice were i.m. immunized with 62.5, 250, or 1,000 ng of OVA antigen per dose delivered in ALTA ® or with Alhydrogel ® , AddaVax™, or Alhydrogel ® + CpG ODN 1018. Where indicated, the boost doses were administered at week 6 after prime. (A, B) Shown are the total OVA doses (ng) (X axis) by the mean anti-OVA IgG1 (log10) titers (Y axis) at week 4 after prime (A) and week 4 after boost (B) . The amount of aluminum (ng Al3+) delivered with each treatment is indicated as a color-coded number on the graph. The AddaVax™ group did not receive any aluminum and is labeled as “n/a” (not applicable). (C, D) Shown are the total OVA doses (ng) (X axis) by the mean percentage of the OVA-specific CD8+ T cells in blood (Y axis) at week 2 after prime (C) and week 2 after boost. (D) N = 4–5/group. OVA, ovalbumin; ALTA, Atomic Layering Thermostable Antigen and Adjuvant.

Article Snippet: For immunizations with liquid OVA EndoFitTM (vac-pova, InvivoGen), the following compounds were used: Alhydrogel ® adjuvant 2% (1:50 OVA: Al3+, Vac-alu-50), AddaVaxTM (vac-adx-10, InvivoGen), ODN 1018 VacciGradeTM (20 μg/dose, vac-1018-1), Poly(I:C) (HMW) VacciGradeTM (40 μg/dose, vac-pic, InvivoGen), and αCD40 antibody (40 μg/dose; clone FGK4.5, BioXcell, Lebanon, NH, USA).

Techniques: Labeling, Adjuvant